Page last updated: 2024-11-04

gatifloxacin and Amebiasis

gatifloxacin has been researched along with Amebiasis in 1 studies

Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.

Amebiasis: Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Thongseesuksai, T1
Wongwai, P1
Boonmars, T1
Sanpool, O1
Laummaunwai, P1

Other Studies

1 other study available for gatifloxacin and Amebiasis

ArticleYear
Evaluating the in vitro efficacy of gatifloxacin, levofloxacin and gentamicin against Acanthamoeba cysts.
    International ophthalmology, 2020, Volume: 40, Issue:2

    Topics: Acanthamoeba; Amebiasis; Animals; Eye Infections, Parasitic; Gatifloxacin; Gentamicins; Humans; Levo

2020